

EudraCT number: 2021-003226-71

Sponsor Company: F. Hoffmann-La Roche Ltd

Study Title: A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration

The study MR42410 was planned to be conducted at European Union (EU), or European Economic Area (EEA) sites. However, no subjects were enrolled in the study and the study ended prematurely. Consequently, study results will not be submitted.